Home LiteratureArticle Details
PMID: 8520966 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects.

Journal of molecular medicine (Berlin, Germany) ·Vol. 73 ·No. 7 ·1995-07-00 ·Pages 333-46

Battegay EJ

Abstract

This review of angiogenesis aims to describe (a) stimuli that either elicit or antagonize angiogenesis, (b) the response of the vasculature to angiogenic or anti-angiogenic stimuli, i.e., processes required for the formation of new vessels, (c) aspects of angiogenesis relating to tissue remodeling and disease, and (d) the potential of angiogenic or antiangiogenic therapeutic measures. Angiogenesis, the formation of new vessels from existing microvessels, is important in embryogenesis, wound healing, diabetic retinopathy, tumor growth, and other diseases. Hypoxia and other as yet ill-defined stimuli drive tumor, inflammatory, and connective tissue cells to generate angiogenic molecules such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), transforming growth factor-beta (TGF-beta), platelet-derived growth factor (PDGF), and others. Natural and synthetic angiogenesis inhibitors such as angiostatin and thalidomide can repress angiogenesis. Angiogenic and antiangiogenic molecules control the formation of new vessels via different mechanisms. VEGF and FGF elicit their effects mainly via direct action on relevant endothelial cells. TGF-beta and PDGF can attract inflammatory or connective tissue cells which in turn control angiogenesis. Additionally, PDGF may act differently on specific phenotypes of endothelial cells that are engaged in angiogenesis or that are of microvascular origin. Thus phenotypic traits of endothelial cells committed to angiogenesis may determine their cellular responses to given stimuli. Processes necessary for new vessel formation and regulated by angiogenic/antiangiogenic molecules include the migration and proliferation of endothelial cells from the microvasculature, the controlled expression of proteolytic enzymes, the breakdown and reassembly of extracellular matrix, and the morphogenic process of endothelial tube formation. In animal models some angiogenesis-dependent diseases can be controlled via induction or inhibition of new vessel formation. Life-threatening infantile hemangiomas are a first established indication for antiangiogenic therapy in humans. Treatment of other diseases by modulation of angiogenesis are currently tested in clinical trials. Thus the manipulation of new vessel formation in angiogenesis-dependent conditions such as wound healing, inflammatory diseases, ischemic heart and peripheral vascular disease, myocardial infarction, diabetic retinopathy, and cancer is likely to create new therapeutic options.

MeSH Terms
Animals Humans Neovascularization, Pathologic/therapy Neovascularization, Physiologic
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Battegay E J
Department of Research and Internal Medicine, University Hospital, Basel, Switzerland.
References (169)
169 references, click to expand
  1. Requirement of vascular integrin alpha v beta 3 for angiogenesis.
    Science. 1994 Apr 22;264(5158):569-71 PMID: 7512751
  2. The possible role of angiogenesis in the metastatic potential of human melanoma. Clinicopathological aspects.
    Melanoma Res. 1993 Feb;3(1):5-14 PMID: 7682462
  3. Regressing thin cutaneous malignant melanomas (< or = 1.0 mm) are associated with angiogenesis.
    Am J Pathol. 1993 Jul;143(1):99-104 PMID: 7686347
  4. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor.
    Lab Invest. 1992 Oct;67(4):519-28 PMID: 1279270
  5. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.
    N Engl J Med. 1994 Dec 1;331(22):1480-7 PMID: 7526212
  6. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin.
    J Biol Chem. 1994 Feb 11;269(6):4355-9 PMID: 8308005
  7. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase.
    J Cell Physiol. 1994 Jul;160(1):194-202 PMID: 7517405
  8. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers.
    Lancet. 1992 Jan 4;339(8784):23-5 PMID: 1345953
  9. Angiogenesis in the female reproductive system.
    FASEB J. 1992 Feb 1;6(3):886-92 PMID: 1371260
  10. Enhanced revascularization of the ischemic limb by angiogenic therapy.
    Circulation. 1993 Jul;88(1):208-15 PMID: 8319335
  11. Vascular endothelial growth factor messenger ribonucleic acid expression in the primate ovary.
    Endocrinology. 1992 Jul;131(1):254-60 PMID: 1612003
  12. Interleukin-8 as a macrophage-derived mediator of angiogenesis.
    Science. 1992 Dec 11;258(5089):1798-801 PMID: 1281554
  13. The type 1 repeats of thrombospondin 1 activate latent transforming growth factor-beta.
    J Biol Chem. 1994 Oct 28;269(43):26783-8 PMID: 7929414
  14. Hypoxia induces glucose transporter expression in endothelial cells.
    Am J Physiol. 1992 Aug;263(2 Pt 1):C326-33 PMID: 1514581
  15. Inhibitory action of transforming growth factor beta on endothelial cells.
    Proc Natl Acad Sci U S A. 1987 Aug;84(16):5600-4 PMID: 2441387
  16. Immature rat ovaries become revascularized rapidly after autotransplantation and show a gonadotropin-dependent increase in angiogenic factor gene expression.
    Endocrinology. 1994 Mar;134(3):1146-54 PMID: 8119153
  17. Platelet-derived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas.
    Lab Invest. 1992 Oct;67(4):529-34 PMID: 1434531
  18. Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis.
    J Cell Physiol. 1993 Jun;155(3):568-78 PMID: 7684043
  19. Angiogenic effects of low molecular weight heparin in patients with stable coronary artery disease: a pilot study.
    J Am Coll Cardiol. 1993 Sep;22(3):635-41 PMID: 8394849
  20. Hypothesis: vasa vasorum and neovascularization of human coronary arteries. A possible role in the pathophysiology of atherosclerosis.
    N Engl J Med. 1984 Jan 19;310(3):175-7 PMID: 6197652
  21. The role of PDGF-BB on the development of the collateral circulation after acute arterial occlusion.
    Growth Factors. 1994;10 (4):299-306 PMID: 7803046
  22. Vascular endothelial growth factor--its role in retinal vascular proliferation.
    N Engl J Med. 1994 Dec 1;331(22):1519-20 PMID: 7526213
  23. Platelet-derived growth factor is angiogenic in vivo.
    Growth Factors. 1992;7(4):261-6 PMID: 1284870
  24. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis.
    Cell. 1993 Mar 26;72(6):835-46 PMID: 7681362
  25. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects.
    J Clin Invest. 1993 Dec;92(6):2620-5 PMID: 7504689
  26. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells.
    Nat Genet. 1994 Oct;8(2):171-6 PMID: 7531056
  27. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer.
    Lancet. 1992 Nov 7;340(8828):1120-4 PMID: 1279332
  28. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers.
    J Natl Cancer Inst. 1994 Mar 2;86(5):356-61 PMID: 7508518
  29. Rat brain capillary endothelial cells express functional PDGF B-type receptors.
    Growth Factors. 1989;2(1):1-8 PMID: 2561393
  30. Media conditioned by smooth muscle cells cultured in a variety of hypoxic environments stimulates in vitro angiogenesis. A relationship to transforming growth factor-beta 1.
    Am J Pathol. 1992 Dec;141(6):1507-16 PMID: 1281623
  31. Human microvascular endothelial cells express receptors for platelet-derived growth factor.
    Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):2021-5 PMID: 1848018
  32. Endothelial cell implantation and survival within experimental gliomas.
    Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9695-9 PMID: 7937875
  33. Platelet-derived growth factor (BB homodimer), transforming growth factor-beta 1, and basic fibroblast growth factor in dermal wound healing. Neovessel and matrix formation and cessation of repair.
    Am J Pathol. 1992 Jun;140(6):1375-88 PMID: 1376557
  34. Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. Implications for the mode of progression of advanced coronary atherosclerosis.
    J Clin Invest. 1993 Aug;92(2):945-51 PMID: 7688768
  35. Growth factors and angiogenesis.
    Cardiovasc Res. 1993 Jul;27(7):1155-61 PMID: 7504584
  36. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only.
    Circulation. 1994 Aug;90(2):649-52 PMID: 8044933
  37. Extent of vascularization as a prognostic indicator in thin (< 0.76 mm) malignant melanomas.
    Am J Pathol. 1994 Sep;145(3):510-4 PMID: 7521576
  38. Endothelial control of vascular tone in large and small coronary arteries.
    J Am Coll Cardiol. 1990 Mar 1;15(3):519-27 PMID: 2406318
  39. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor.
    Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9267-71 PMID: 1924389
  40. Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis.
    J Clin Invest. 1993 Mar;91(3):977-85 PMID: 7680672
  41. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy.
    N Engl J Med. 1992 May 28;326(22):1456-63 PMID: 1489383
  42. The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors.
    Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1281-5 PMID: 1311092
  43. Angiogenesis in cancer, vascular, rheumatoid and other disease.
    Nat Med. 1995 Jan;1(1):27-31 PMID: 7584949
  44. Pituitary follicular cells secrete an inhibitor of aortic endothelial cell growth: identification as leukemia inhibitory factor.
    Proc Natl Acad Sci U S A. 1992 Jan 15;89(2):698-702 PMID: 1370585
  45. In vitro angiogenic and proteolytic properties of bovine lymphatic endothelial cells.
    Exp Cell Res. 1994 Feb;210(2):298-305 PMID: 7507853
  46. SPARC is a source of copper-binding peptides that stimulate angiogenesis.
    J Cell Biol. 1994 May;125(4):929-43 PMID: 7514608
  47. Transforming growth factor-beta activity is potentiated by heparin via dissociation of the transforming growth factor-beta/alpha 2-macroglobulin inactive complex.
    J Cell Biol. 1989 Jul;109(1):441-8 PMID: 2473082
  48. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1.
    Science. 1994 Sep 9;265(5178):1582-4 PMID: 7521539
  49. Physiological consequences of loss of plasminogen activator gene function in mice.
    Nature. 1994 Mar 31;368(6470):419-24 PMID: 8133887
  50. The diabetic rat as an impaired wound healing model: stimulatory effects of transforming growth factor-beta and basic fibroblast growth factor.
    Biotechnol Ther. 1989-1990;1(1):55-68 PMID: 2562644
  51. Toward an understanding of angiogenesis: search and discovery.
    Perspect Biol Med. 1985 Autumn;29(1):10-36 PMID: 2415913
  52. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation.
    Development. 1992 Feb;114(2):521-32 PMID: 1592003
  53. Modulation of extracellular matrix proteins by endothelial cells undergoing angiogenesis in vitro.
    Arterioscler Thromb. 1991 Jul-Aug;11(4):805-15 PMID: 1712229
  54. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue.
    J Exp Med. 1994 Jul 1;180(1):341-6 PMID: 8006592
  55. Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo.
    Lab Invest. 1994 Sep;71(3):374-9 PMID: 7933988
  56. A role for sialyl Lewis-X/A glycoconjugates in capillary morphogenesis.
    Nature. 1993 Sep 16;365(6443):267-9 PMID: 7690465
  57. De novo generation of permanent neovascularized soft tissue appendages by platelet-derived growth factor.
    J Clin Invest. 1994 Nov;94(5):1757-63 PMID: 7525647
  58. PDGF and TGF-alpha act synergistically to improve wound healing in the genetically diabetic mouse.
    J Surg Res. 1994 Jun;56(6):562-70 PMID: 8015312
  59. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.
    J Clin Invest. 1994 Dec;94(6):2493-503 PMID: 7989608
  60. Vascular targeting and the inhibition of angiogenesis.
    Ann Oncol. 1994;5 Suppl 4:45-50 PMID: 7520262
  61. Thalidomide is an inhibitor of angiogenesis.
    Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4082-5 PMID: 7513432
  62. Immunohistochemical study of intimal microvessels in coronary atherosclerosis.
    Am J Pathol. 1993 Jul;143(1):164-72 PMID: 7686341
  63. Expression of platelet-derived endothelial cell growth factor in Escherichia coli and confirmation of its thymidine phosphorylase activity.
    Biochemistry. 1992 Dec 8;31(48):12141-6 PMID: 1457409
  64. Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB.
    Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):393-7 PMID: 8380638
  65. The collateral circulation of the heart.
    Prog Cardiovasc Dis. 1988 Jul-Aug;31(1):57-77 PMID: 3293120
  66. Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: a morphometric study.
    J Pathol. 1992 Nov;168(3):257-62 PMID: 1281874
  67. Angiogenesis can be stimulated or repressed in vivo by a change in GM3:GD3 ganglioside ratio.
    Lab Invest. 1992 Dec;67(6):711-5 PMID: 1281244
  68. Erythropoietin receptor mRNA expression in human endothelial cells.
    Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3974-8 PMID: 8171022
  69. Recent insights into coronary collateral circulation.
    Circulation. 1992 Mar;85(3):1197-204 PMID: 1371432
  70. Response of the FSaII fibrosarcoma to antiangiogenic modulators plus cytotoxic agents.
    Anticancer Res. 1993 Nov-Dec;13(6A):2101-6 PMID: 7507654
  71. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma.
    Nature. 1994 Oct 20;371(6499):674-80 PMID: 7935812
  72. Growth factors in endothelial regeneration.
    Cardiovasc Res. 1993 Jul;27(7):1162-72 PMID: 8252574
  73. Correlation between angiogenesis and basic fibroblast growth factor expression in experimental brain infarct.
    Stroke. 1994 Aug;25(8):1651-7 PMID: 7518971
  74. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels.
    Cell. 1994 Dec 30;79(7):1157-64 PMID: 7528107
  75. Biphasic effect of transforming growth factor-beta 1 on in vitro angiogenesis.
    Exp Cell Res. 1993 Feb;204(2):356-63 PMID: 7679998
  76. Thrombin mitogenic responses and protein phosphorylation are different in cultured human endothelial cells derived from large and microvessels.
    Exp Cell Res. 1989 Dec;185(2):363-72 PMID: 2599027
  77. Identification of multiple active growth factors in basement membrane Matrigel suggests caution in interpretation of cellular activity related to extracellular matrix components.
    Exp Cell Res. 1992 Sep;202(1):1-8 PMID: 1511725
  78. Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol.
    Cell Immunol. 1994 Aug;157(1):291-9 PMID: 7518753
  79. Reorganization of basement membrane matrices by cellular traction promotes the formation of cellular networks in vitro.
    Lab Invest. 1992 May;66(5):536-47 PMID: 1374138
  80. Dose responsive effects of PDGF-BB, PDGF-AA, EGF, and bFGF on granulation tissue in a guinea pig partial thickness skin excision model.
    Growth Factors. 1993;8(4):307-14 PMID: 8347346
  81. TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop.
    Cell. 1990 Nov 2;63(3):515-24 PMID: 2171777
  82. Angiogenesis during human extraembryonic development involves the spatiotemporal control of PDGF ligand and receptor gene expression.
    Development. 1991 Nov;113(3):749-54 PMID: 1668277
  83. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma.
    Cell. 1994 Oct 21;79(2):315-28 PMID: 7525077
  84. Embryonic angiogenesis factors.
    Pharmacol Ther. 1991;51(3):371-6 PMID: 1792240
  85. Release of transforming growth factor-beta 1 from the pericellular matrix of cultured fibroblasts and fibrosarcoma cells by plasmin and thrombin.
    J Biol Chem. 1992 Dec 15;267(35):25378-84 PMID: 1281156
  86. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture.
    J Cell Biol. 1989 Jul;109(1):309-15 PMID: 2526131
  87. Production of angiogenic activity by human monocytes requires an L-arginine/nitric oxide-synthase-dependent effector mechanism.
    Proc Natl Acad Sci U S A. 1994 May 10;91(10):4190-4 PMID: 7514298
  88. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis.
    Endocrinology. 1993 Sep;133(3):1292-9 PMID: 7689950
  89. Oxygen tension regulates the expression of the platelet-derived growth factor-B chain gene in human endothelial cells.
    J Clin Invest. 1990 Aug;86(2):670-4 PMID: 2384608
  90. Scatter factor induces blood vessel formation in vivo.
    Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1937-41 PMID: 7680481
  91. Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin.
    J Cell Biol. 1990 Apr;110(4):1361-7 PMID: 2139036
  92. Inhibition of basement membrane biosynthesis prevents angiogenesis.
    J Pharmacol Exp Ther. 1988 Feb;244(2):729-33 PMID: 2450202
  93. Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis.
    J Clin Invest. 1993 May;91(5):2235-43 PMID: 7683699
  94. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation.
    Cell. 1991 Jan 25;64(2):327-36 PMID: 1703045
  95. A cartilage-derived inhibitor of neovascularization and metalloproteinases.
    Clin Exp Rheumatol. 1993 Mar-Apr;11 Suppl 8:S67-9 PMID: 7686834
  96. An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes.
    Proc Natl Acad Sci U S A. 1989 Jun;86(12):4544-8 PMID: 2734305
  97. Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts.
    J Clin Invest. 1994 Aug;94(2):623-30 PMID: 7518840
  98. Angiogenic activity of enzymes.
    Nature. 1994 Mar 17;368(6468):198 PMID: 7511797
  99. Angiogenic growth factors.
    Prog Growth Factor Res. 1990;2(1):71-9 PMID: 1716501
  100. Tumor angiogenesis: review of current applications in tumor prognostication.
    Semin Diagn Pathol. 1993 Nov;10(4):302-13 PMID: 7511250
  101. Characterization of monocyte adherence to human macrovascular and microvascular endothelial cells.
    J Immunol. 1990 Jul 15;145(2):510-8 PMID: 1973184
  102. Phenotypic diversity in cultured cerebral microvascular endothelial cells.
    In Vitro Cell Dev Biol. 1988 May;24(5):435-44 PMID: 2836356
  103. Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor.
    Diabetologia. 1993 Apr;36(4):282-91 PMID: 7682976
  104. Interaction of the allogeneic state and hypercholesterolemia in arterial lesion formation in experimental cardiac allografts.
    Arterioscler Thromb. 1994 May;14(5):734-45 PMID: 8172851
  105. Expression of decorin by sprouting bovine aortic endothelial cells exhibiting angiogenesis in vitro.
    Exp Cell Res. 1992 Dec;203(2):395-401 PMID: 1281110
  106. Molecular biologic concepts of coronary anastomoses.
    J Am Coll Cardiol. 1990 Mar 1;15(3):513-8 PMID: 2406317
  107. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis.
    Nature. 1992 Oct 29;359(6398):843-5 PMID: 1279431
  108. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis.
    Cancer Res. 1993 Dec 1;53(23):5822-7 PMID: 7694795
  109. The effects of platelet-derived growth factor in cultured microvessel endothelial cells.
    Endocrinology. 1989 Apr;124(4):1841-8 PMID: 2924726
  110. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms.
    J Clin Invest. 1993 Jan;91(1):153-9 PMID: 8380810
  111. Differential expression of extracellular proteins is correlated with angiogenesis in vitro.
    Lab Invest. 1991 Feb;64(2):174-86 PMID: 1705300
  112. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model.
    J Clin Invest. 1994 Feb;93(2):662-70 PMID: 7509344
  113. Angiogenesis.
    J Biol Chem. 1992 Jun 5;267(16):10931-4 PMID: 1375931
  114. Inhibition of IGF-I and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment for ocular neovascularization.
    Regul Pept. 1993 Oct 20;48(1-2):267-78 PMID: 7505469
  115. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity.
    J Cell Biol. 1993 Jul;122(2):497-511 PMID: 7686555
  116. 1992 Mack Forster Award Lecture. Review. Regulation of angiogenesis in vitro.
    Eur J Clin Invest. 1992 Aug;22(8):504-15 PMID: 1385149
  117. Thrombospondin binds and activates the small and large forms of latent transforming growth factor-beta in a chemically defined system.
    J Biol Chem. 1994 Oct 28;269(43):26775-82 PMID: 7929413
  118. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.
    Nature. 1993 Apr 29;362(6423):841-4 PMID: 7683111
  119. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant.
    Nature. 1994 Feb 10;367(6463):576-9 PMID: 8107827
  120. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth.
    J Cell Biol. 1992 Nov;119(3):629-41 PMID: 1383237
  121. Angiogenesis and colonization in the tumor metastatic process: basic and applied advances.
    FASEB J. 1994 Apr 1;8(6):401-7 PMID: 7513289
  122. Clinical prognostic significance of tumour angiogenesis.
    Ann Oncol. 1994 Apr;5(4):305-11 PMID: 7521203
  123. Angiogenic macrophages produce the angiogenic inhibitor thrombospondin 1.
    Am J Pathol. 1993 Sep;143(3):678-84 PMID: 7689791
  124. Tissue localization of beta receptors for platelet-derived growth factor and platelet-derived growth factor B chain during wound repair in humans.
    J Clin Invest. 1993 May;91(5):2065-75 PMID: 8486774
  125. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth.
    Nature. 1994 Mar 17;368(6468):237-9 PMID: 7511798
  126. Antigenic heterogeneity of vascular endothelium.
    Am J Pathol. 1992 Sep;141(3):673-83 PMID: 1519671
  127. Treatment of childhood angiomatous diseases with recombinant interferon alfa-2a.
    J Pediatr. 1991 Jan;118(1):59-66 PMID: 1986099
  128. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.
    Nature. 1992 Oct 29;359(6398):845-8 PMID: 1279432
  129. Angiogenesis and endothelial cell function.
    Arzneimittelforschung. 1994 Mar;44(3A):416-7 PMID: 7514414
  130. Modulation of platelet-derived growth factor receptor expression in microvascular endothelial cells during in vitro angiogenesis.
    J Clin Invest. 1994 Jan;93(1):131-9 PMID: 7506710
  131. The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma. A quantitative histologic study.
    Am J Pathol. 1988 Nov;133(2):419-23 PMID: 3189515
  132. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor.
    Science. 1992 Sep 4;257(5075):1401-3 PMID: 1382313
  133. Functional significance of collaterals during ameroid-induced coronary stenosis in conscious dogs. Interrelationships among regional shortening, regional flow and grade of coronary stenosis.
    Circulation. 1983 May;67(5):1001-8 PMID: 6831663
  134. Inhibition of endothelial regeneration by type-beta transforming growth factor from platelets.
    Science. 1986 Sep 5;233(4768):1078-80 PMID: 3461562
  135. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis.
    Microvasc Res. 1977 Jul;14(1):53-65 PMID: 895546
  136. Latent transforming growth factor-beta 1 associates to fibroblast extracellular matrix via latent TGF-beta binding protein.
    J Cell Biol. 1994 Jan;124(1-2):171-81 PMID: 8294500
  137. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells.
    Biochem Biophys Res Commun. 1991 Dec 16;181(2):902-6 PMID: 1755866
  138. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides.
    Science. 1990 Jan 5;247(4938):77-9 PMID: 1688470
  139. Angiogenic processes in the pathogenesis of human coronary atherosclerosis.
    Curr Top Pathol. 1993;87:47-58 PMID: 7510224
  140. Extracellular matrix and cell shape: potential control points for inhibition of angiogenesis.
    J Cell Biochem. 1991 Nov;47(3):236-41 PMID: 1724246
  141. Tumor necrosis factor alpha-induced angiogenesis depends on in situ platelet-activating factor biosynthesis.
    J Exp Med. 1994 Jul 1;180(1):377-82 PMID: 7516414
  142. Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma.
    J Exp Med. 1994 May 1;179(5):1409-15 PMID: 7513008
  143. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor.
    Cancer Res. 1991 Nov 15;51(22):6180-4 PMID: 1718597
  144. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells.
    J Cell Physiol. 1992 Dec;153(3):557-62 PMID: 1447317
  145. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma.
    J Clin Oncol. 1994 Mar;12(3):454-66 PMID: 7509851
  146. Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. A novel strategy for the therapy of KS.
    J Clin Invest. 1994 Nov;94(5):1736-46 PMID: 7525646
  147. Interleukin-8. A corneal factor that induces neovascularization.
    Am J Pathol. 1992 Dec;141(6):1279-84 PMID: 1281615
  148. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR.
    J Biol Chem. 1994 Oct 14;269(41):25646-54 PMID: 7929268
  149. Isolation and characterization of vasoformative endothelial cells from the rat aorta.
    In Vitro Cell Dev Biol Anim. 1994 Jun;30A(6):394-9 PMID: 7522101
  150. Stable expression of human platelet-derived growth factor B chain by bovine aortic endothelial cells. Matrix association and selective proteolytic cleavage by thrombin.
    J Biol Chem. 1994 Jul 1;269(26):17734-40 PMID: 8021286
  151. PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors.
    J Cell Biol. 1994 May;125(4):917-28 PMID: 7514607
  152. Inhibition of endothelial cell proliferation by platelet factor-4 involves a unique action on S phase progression.
    J Cell Biol. 1994 Nov;127(4):1121-7 PMID: 7962072
  153. Downregulation of endothelial cell thrombospondin 1 enhances in vitro angiogenesis.
    J Vasc Res. 1994 May-Jun;31(3):178-85 PMID: 7511943
  154. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis.
    J Immunol. 1994 Apr 15;152(8):4149-56 PMID: 7511670
  155. Fibrogenic cytokines and connective tissue production.
    FASEB J. 1994 Aug;8(11):854-61 PMID: 7520879
  156. Growth factors are released by mechanically wounded endothelial cells.
    J Cell Biol. 1989 Aug;109(2):811-22 PMID: 2760113
  157. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops.
    Cancer Res. 1992 Jun 1;52(11):3213-9 PMID: 1317261
  158. Three novel synthetic retinoids, Re 80, Am 580 and Am 80, all exhibit anti-angiogenic activity in vivo.
    Eur J Pharmacol. 1993 Nov 2;249(1):113-6 PMID: 7506665
  159. Stimulation and inhibition of angiogenesis by placental proliferin and proliferin-related protein.
    Science. 1994 Dec 2;266(5190):1581-4 PMID: 7527157
  160. The interaction of HGF-SF with other cytokines in tumor invasion and angiogenesis.
    EXS. 1993;65:301-10 PMID: 7678533
  161. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy.
    Am J Ophthalmol. 1994 Oct 15;118(4):445-50 PMID: 7943121
  162. AIDS-associated Kaposi's sarcoma cells in culture express vascular endothelial growth factor.
    Biochem Biophys Res Commun. 1992 Mar 31;183(3):1167-74 PMID: 1567395
  163. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model.
    Am J Pathol. 1994 Sep;145(3):574-84 PMID: 7521577
  164. Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma.
    N Engl J Med. 1991 Jan 3;324(1):1-8 PMID: 1701519
  165. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene.
    Cell. 1989 Feb 10;56(3):345-55 PMID: 2464438
  166. Coronary collateral recruitment: functional significance and relation to rate of vessel closure.
    Am Heart J. 1991 Mar;121(3 Pt 1):876-80 PMID: 2000755
  167. Pentosan inhibits angiogenesis in vitro and suppresses prostate tumor growth in vivo.
    Anticancer Res. 1993 Nov-Dec;13(6A):2143-7 PMID: 7507655
  168. Endothelial cells exhibiting angiogenesis in vitro proliferate in response to TGF-beta 1.
    J Cell Biochem. 1993 Aug;52(4):414-30 PMID: 7693728
  169. Intracoronary injection of basic fibroblast growth factor enhances angiogenesis in infarcted swine myocardium.
    J Am Coll Cardiol. 1993 Dec;22(7):2001-6 PMID: 7504006
Article Info
Journal
Journal of molecular medicine (Berlin, Germany)
Abbr.
J Mol Med (Berl)
ISSN
0946-2716
DOI
10.1007/BF00192885
Published
1995-07-00
Pages
333-46
Language
English
Region
Germany
NLM ID
9504370
Subset
IM
External Links
PubMed source DOI: 10.1007/BF00192885 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2